Forbes November 13, 2024
With the U.S. election in the rearview mirror, we have arrived at a defining moment for the future of medical innovation.
Drug developers, investors, and biotech entrepreneurs face a policy landscape in the U.S. that many in the industry believe could be improved, in order to hasten the development of new medicines for patients in need. From my vantage point as an insider in the pharmaceutical industry who leads Bayer’s venture capital arm as well as its pharma business development and licensing division, here are three ways the incoming Trump administration could create more favorable policies for drug development:
1. Incentivize the risk-takers with strong patents
It is no secret that the biopharma industry is filled with failure. Nine out...
Today's Sponsors
Today's Sponsor